Pharmacotherapy considerations for pediatric acute agitation management in the emergency department.

IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY American Journal of Health-System Pharmacy Pub Date : 2024-11-22 DOI:10.1093/ajhp/zxae194
Kimberly P Mills, Megan Kemper, Natchanan Charatcharungkiat, George M Hoganson
{"title":"Pharmacotherapy considerations for pediatric acute agitation management in the emergency department.","authors":"Kimberly P Mills, Megan Kemper, Natchanan Charatcharungkiat, George M Hoganson","doi":"10.1093/ajhp/zxae194","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To review the current literature regarding the pharmacological management of acute agitation in pediatric patients and practical considerations when comparing agents for empiric use in the emergency department (ED).</p><p><strong>Summary: </strong>ED providers play an integral role in the management of acute agitation in pediatric patients. The development of acute agitation is multifactorial, and patients may quickly escalate upon arrival or while boarding in the ED. Non-pharmacological de-escalation strategies should be prioritized. If a patient poses a safety risk to themself or staff members, the administration of pharmacological treatment may be necessary to target the underlying cause and allow for the patient to safely engage in assessment and treatment. There is limited guidance regarding medication selection and dosing for acute agitation in pediatrics despite being a key facet of multimodal management.</p><p><strong>Conclusion: </strong>The literature regarding pharmacotherapy for acute agitation management in pediatric patients remains scarce. Medications utilized vary depending on institutional practice as well as provider preference. Evidence suggests that implementing an institutional protocol for pediatric acute agitation in the ED may improve patient outcomes. Additional studies are needed optimize the pharmacological management of acute pediatric agitation and patient outcomes in the ED.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"e727-e741"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Health-System Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajhp/zxae194","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To review the current literature regarding the pharmacological management of acute agitation in pediatric patients and practical considerations when comparing agents for empiric use in the emergency department (ED).

Summary: ED providers play an integral role in the management of acute agitation in pediatric patients. The development of acute agitation is multifactorial, and patients may quickly escalate upon arrival or while boarding in the ED. Non-pharmacological de-escalation strategies should be prioritized. If a patient poses a safety risk to themself or staff members, the administration of pharmacological treatment may be necessary to target the underlying cause and allow for the patient to safely engage in assessment and treatment. There is limited guidance regarding medication selection and dosing for acute agitation in pediatrics despite being a key facet of multimodal management.

Conclusion: The literature regarding pharmacotherapy for acute agitation management in pediatric patients remains scarce. Medications utilized vary depending on institutional practice as well as provider preference. Evidence suggests that implementing an institutional protocol for pediatric acute agitation in the ED may improve patient outcomes. Additional studies are needed optimize the pharmacological management of acute pediatric agitation and patient outcomes in the ED.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
急诊科儿科急性躁动治疗的药物治疗注意事项。
免责声明:为了加快文章的出版速度,AJHP在接受稿件后会尽快在网上发布。被录用的稿件已经过同行评审和校对,但在进行技术格式化和作者校对之前会在网上发布。目的:综述有关儿科患者急性躁动的药物治疗的现有文献,以及比较急诊科(ED)经验性用药时的实际考虑因素。摘要:急诊科医生在儿科患者急性躁动的治疗中发挥着不可或缺的作用。急性躁动的发生是多因素的,患者在到达急诊科或在急诊科寄宿期间可能会迅速加重。应优先采用非药物缓解策略。如果患者对自身或工作人员构成安全风险,则有必要针对根本原因进行药物治疗,使患者能够安全地接受评估和治疗。儿科急性躁动的药物选择和剂量是多模式管理的一个重要方面,但有关儿科急性躁动药物选择和剂量的指导却很有限:有关儿科患者急性躁动治疗药物疗法的文献仍然很少。所使用的药物因医疗机构的做法和医护人员的偏好而有所不同。有证据表明,在急诊室实施针对儿科急性躁动的机构方案可改善患者的预后。需要开展更多研究,以优化急诊室对儿科急性躁动的药物治疗和患者预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.90
自引率
18.50%
发文量
341
审稿时长
3-8 weeks
期刊介绍: The American Journal of Health-System Pharmacy (AJHP) is the official publication of the American Society of Health-System Pharmacists (ASHP). It publishes peer-reviewed scientific papers on contemporary drug therapy and pharmacy practice innovations in hospitals and health systems. With a circulation of more than 43,000, AJHP is the most widely recognized and respected clinical pharmacy journal in the world.
期刊最新文献
Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025). A call to action: Studying the shortened duration of ceftriaxone for inpatient management of acute uncomplicated cystitis. Impact of a pharmacist-led intervention on prostate cancer illness perception. Pharmacotherapy considerations for pediatric acute agitation management in the emergency department. Central lines, aseptic batching services, and infection rates: A pharmacy-led initiative of intravenous tube priming within a NICU.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1